Known for lower misuse potential and a smoother effect profile, lisdexamfetamine stands out in ADHD treatment. This article explores what makes it unique among stimulants.
Harish Kavirajan revisits the use of antipsychotics in depression, weighing small benefits against serious risks, like tardive dyskinesia and metabolic issues.
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.